Drug Trial Radar · NCT01771458
A Randomized Phase II Trial Comparing Therapy Based on Tumor Molecular Profiling Versus Conventional Therapy in Patients With Refractory Cancer
Last checked: Nov 19, 2026Latest source record: Nov 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
742
Actual
Start
Oct 2012
Primary completion
Oct 2016
Study completion Dec 2016
Sponsor
- Lead sponsor
- Institut CurieAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 18, 2013
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
SHIVA is a proof of concept randomized phase II trial which compares two treatment strategies for patients with refractory cancer. From a tumor biopsy, a molecular profile of the disease is established (mutations, amplifications, hormone receptor status). If a molecular abnormality is identified for which an approved targeted agent is available, patients are randomized randomized between two arms: * Targeted therapy based on the molecular profile * Conventional therapy based on investigator's choice. A cross-over is proposed at disease progression.
Conditions
- Reccurent/Metastatic Solid Tumor Disease
Interventions
Targeted therapy based on molecular profiling : ImatinibDrug
Tumor biopsyProcedure
Standard ChemotherapyDrug
Targeted therapy based on molecular profiling : EverolimusDrug
Targeted therapy based on molecular profiling : VemurafenibDrug
Targeted therapy based on molecular profiling : SorafenibDrug
Targeted therapy based on molecular profiling : ErlotinibDrug
Targeted therapy based on molecular profiling : Lapatinib + TrastuzumabDrug
Targeted therapy based on molecular profiling : DasatinibDrug
Targeted therapy based on molecular profiling : Tamoxifen (or letrozole if contra-indication)Drug
Targeted therapy based on molecular profiling : AbirateroneDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Patient's progression free survival (according RECIST 1.1) of targeted therapy based on molecular profiling versus conventional chemotherapy.
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Centre régional de lutte contre le cancer de Bourgogne Georges François Leclerc
Dijon, France
Centre Leon Berard
Lyon, France
Institut Paoli Calmettes
Marseille, France
Insitut Curie
Paris, France
Institut Curie Hopital Rene Huguenin
Saint-Cloud, France
Institut de cancérologie de l'Ouest Centre René Gauducheau
Saint-Herblain, France
Institut Claudius Régaud
Toulouse, France
Centre Alexis Vautrin
Vandœuvre-lès-Nancy, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.